clinical myocardial injuries, especially in the setting of ischemia. The aim of this study was to study speckle tracking longitudinal strain for early risk stratification in NSTEMI with no sign of myocardial dysfunction (left ventricular ejection fraction (LVEF) > 50% and no abnormality of regional wall motion).
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Early detection of cardiac involvement in sarcoidosis with 2D speckle tracking echocardiography Elie Dan Schouver (1), Pierre Gibelin (1), Olivier Chiche (1), Viviane Queyrel (2), Nathalie Thieulie (2), Emile Ferrari (1), Pamela Moceri (1) (1) CHU Pasteur, Cardiologie, Nice, CHU L'Archet, Méde-cine interne, Nice, France Background: Cardiac sarcoidosis (CS) is associated with high morbidity and sudden death. Currently, cardiac magnetic resonance (CMR) is the most sensitive method for the diagnosis of CS, however as CMR is being positive relatively late, new imaging methods to improve the early diagnosis of CS are lacking.
The aim: of this study was to assess the role of left ventricular (LV) strain estimated by 2D speckle tracking imaging in patients with newly diagnosed sarcoidosis without cardiac involvement according to the current guidelines.
Methods and Results:
We performed a prospective cohort study including 10 patients with newly diagnosed sarcoidosis and normal cardiac function as assessed by classic echocardiography and CMR and 10 healthy age-and gender-matched controls. All patients underwent a comprehensive LV strain echocardiographic study. Speckle tracking analysis was performed by 2 experienced cardiologists blinded to each other and to clinical data. Mean age of patients was 53±14 years old (5 women). All patients presented mediastinal lymphadenopathy, 1 had renal involvement and 4 had pulmonary manifestations. Compared with controls, LV longitudinal strain was reduced: long axis 
Conclusion:
In this pilot study, Speckle-tracking echocardiography revealed impaired LV longitudinal strain in 100% of patients with normal CMR. Decreased longitudinal LV strain could represent an early sign of myocardial involvement in sarcoidosis patients. Therefore further assessment of cardiac deformation imaging in the setting of sarcoidosis is needed to improve the diagnosis of CS (figure above). Background: Antibody-mediated rejection (AMR) is characterized by histopathological and immunophenotypic findings such as activated endothelial cells, intravascular macrophages and evidence of capillary C4d deposition. This inflammatory reaction could be followed by diffuse fibrosis. Cardiac magnetic resonance (CMR) with recently T1 mapping is a promising technique to identify diffuse myocardial fibrosis. The purpose of this study was to assess T1 mapping in patients with AMR.
Method: 2 patients with clinical AMR (histopathological and immunophenotypic findings, presence of donor-specific allo antibodies and allograft dysfunction) performed a CMR study one week (for the first patient) and 3 weeks (for the second patient) after the treatment of AMR (plasmapheresis, IV Immunoglobulins and Rituximab). Images were acquired on a 1.5 Tesla scanner (Siemens) including T1 mapping using a shortened modified looklocker inversion-recovery sequence and T2 mapping in a matched mid-ventricular short axis slice using a black-blood single shot fast spin echo pulse sequence. Segmental and global T1 values were measured before and 15 minutes after administration of 0.2 mmol/kg of Gadoteric acid and compared to our cohort of 17 controls.
Results: Mean non contrast T1 values were significantly higher in heart transplants patients compared to controls (1100±5ms vs 947±29ms, P <0.001). Segmental T1 values were significantly higher in the 6 regions of interest compared to controls (P <0.001 in all segments). Mean post contrast T1 values were not significantly different in patients and controls. Mean T2 value was higher in patients compared to controls (73±13 vs 50± 4ms), suggesting the presence of global edema.
Heart transplant patients with clinical antibody-mediated rejection show a significant increased global and segmental non contrast T1 values suggesting the presence of diffuse myocardial fibrosis. Further studies are required to confirm these data. 
